<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE - hydrocortisone, neomycin sulfate and polymyxin b sulfate suspension </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>Neomycin and Polymyxin B Sulfates and Hydrocortisone OTIC Suspension, USPSterile</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>Neomycin and Polymyxin B Sulfates and Hydrocortisone OTIC Suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use. Each mL contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and hydrocortisone 10 mg (1%). The vehicle contains thimerosal 0.01% (added as a preservative) and the inactive ingredients cetyl alcohol, propylene glycol, polysorbate 80, glacial acetic acid and Water for Injection.</p>
<p>Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of <span class="Italics">Streptomyces fradiae </span>Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis. The structural formula are:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c03c099d-dd34-4731-8f50-ec5c7126f7de&amp;name=MM1.jpg"></p>
<p>Neomycin B (R<span class="Sub">1</span>=H, R<span class="Sub">2</span>=CH<span class="Sub">2</span>NH<span class="Sub">2</span>)</p>
<p>Neomycin C (R<span class="Sub">1</span>=CH<span class="Sub">2</span>NH<span class="Sub">2</span>, R<span class="Sub">2</span>=H)</p>
<p>Polymyxin B sulfate is the sulfate salt of polymyxin B<span class="Sub">1</span> and B<span class="Sub">2</span>, which are produced by the growth of <span class="Italics">Bacillus polymyxa </span>(Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formula are:</p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c03c099d-dd34-4731-8f50-ec5c7126f7de&amp;name=MM2.jpg"></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c03c099d-dd34-4731-8f50-ec5c7126f7de&amp;name=MM3.jpg"></p>
<p>Hydrocortisone, 11β,17, 21-trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is:</p>
<p><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c03c099d-dd34-4731-8f50-ec5c7126f7de&amp;name=MM4.jpg"></p>
<p></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>Corticoids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body's defense mechanism against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.</p>
<p>The anti-infective components in the combination are included to provide action against specific organisms susceptible to them. Neomycin sulfate and polymyxin B sulfate together are considered active against the following microorganisms: <span class="Italics">Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella-Enterobacter </span>species, <span class="Italics">Neisseria </span>species, and <span class="Italics">Pseudomonas aeruginosa. </span>This product does not provide adequate coverage against <span class="Italics">Serratia marcescens </span>and streptococci, including <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p>The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>For the treatment of superficial <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>This product is contraindicated in those individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components, and in herpes simplex, <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<p>Neomycin can induce permanent <span class="product-label-link" type="condition" conceptid="374366" conceptname="Sensorineural hearing loss">sensorineural hearing loss</span> due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days (see <span class="Underline"><a href="#splSectionPrecautionsGeneral">PRECAUTIONS—General</a></span>). Patients being treated with eardrops containing neomycin should be under close clinical observation. Neomycin and Polymyxin B Sulfates and Hydrocortisone OTIC Suspension should not be used in any patient with a perforated tympanic membrane.</p>
<p>Discontinue promptly if sensitization or irritation occurs.</p>
<p>Neomycin sulfate may cause cutaneous sensitization. A precise incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (primarily <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>) due to topical neomycin is not known.</p>
<p>When using neomycin-containing products to control <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span> in the chronic dermatoses, such as chronic <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span> or <span class="product-label-link" type="condition" conceptid="4148876" conceptname="Stasis dermatitis">stasis dermatitis</span>, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, dry scaling, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin-containing applications should be avoided for the patient thereafter.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p>As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi.</p>
<p>If the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not improved after 1 week, cultures and susceptibility tests should be repeated to verify the identity of the organism and to determine whether therapy should be changed.</p>
<p>Treatment should not be continued for longer than 10 days.</p>
<p>Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: kanamycin, paromomycin, streptomycin, and possibly gentamicin.</p>
<p>Information for Patients: Avoid contaminating the dropper with material from the ear, fingers, or other source. This caution is necessary if the <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of the drops is to be preserved.</p>
<p>If sensitization or irritation occurs, discontinue use immediately and contact your physician.</p>
<p>Do not use in the eyes.</p>
<p>SHAKE WELL BEFORE USING.</p>
<p>
 
</p>
<p></p>
<p>Systemic effects of excessive levels of hydrocortisone may include a reduction in the number of circulating eosinophils and a decrease in urinary excretion of 17-hydroxycorticosteroids.</p>
<p>
 
</p>
<p></p>
<p>Long-term studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity attributable to oral administration of corticosteroids.</p>
<p>
 
</p>
<p></p>
<p>Pregnancy Category C. Corticosteroids have been shown to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 to 18 of gestation and in mice when applied topically at a concentration of 15% on days 10 to 13 of gestation. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>
 
</p>
<p></p>
<p>Hydrocortisone appears in human milk following oral administration of the drug. Since systemic absorption of hydrocortisone may occur when applied topically, caution should be exercised when Neomycin and Polymyxin B Sulfates and Hydrocortisone OTIC Suspension is used by a nursing woman.</p>
<p>
 
</p>
<p></p>
<p>The safety and effectiveness of Neomycin and Polymyxin B Sulfates and Hydrocortisone OTIC Suspension in <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span> have been established in the pediatric age group 2 years to 16 years of age. There is inadequate data to establish safety and effectiveness in <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span> for pediatric patients under 2 years of age.<span class="Sup">1</span></p>
<p>
 
</p>
<p></p>
<p>Clinical studies of Neomycin and Polymyxin B Sulfates and Hydrocortisone OTIC Suspension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>Neomycin occasionally causes skin sensitization. <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> have also been reported (see <span class="Underline"><a href="#splSectionWarnings">WARNINGS</a></span>). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span> occurred in two of 2,175 (0.09%) individuals in the general population.<span class="Sup">2</span> In another study, the incidence was found to be approximately 1%.<span class="Sup">3</span></p>
<p>The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, irritation, dryness, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>, hypopigmentation, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>, maceration of the skin, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>, <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, and <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">miliaria</span>.  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Stinging</span> and burning have been reported rarely when this product has gained access to the middle ear.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>Therapy with this product should be limited to 10 consecutive days.</p>
<p>The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator.</p>
<p>For adults, 4 drops of the suspension should be instilled into the affected ear 3 or 4 times daily. For infants and children, 3 drops are suggested because of the smaller capacity of the ear canal.</p>
<p>The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear. If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the suspension. This wick should be kept moist by adding further suspension every 4 hours. The wick should be replaced at least once every 24 hours.</p>
<p>SHAKE WELL BEFORE USING.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension, USP is available in a DROP-TAINER* bottle containing 10mL NDC 61314-645-11.</p>
<p>* DROP-TAINER is a Registered trademark of Alcon Manufacturing, Ltd.</p>
<p>Store at 15° to 25°C (59° to 77°F).</p>
<p>Rx Only</p>
<p>Also Available: Neomycin and Polymyxin B Sulfates and Hydrocortisone OTIC Solution, USP bottle of 10 mL with sterilized dropper.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-10"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"></p>
<p>1. Jones RN, Milazzo J, Seidlin M. Ofloxacin Otic Solution for Treatment of <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">Otitis Externa</span> in Children and Adults. <span class="Italics">Arch Otolaryngol Head Neck Surgery </span>1997;123:1193-1200.</p>
<p>2. Leyden JJ, Kligman AM. <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span> to neomycin sulfate. <span class="Italics">JAMA</span>. 1979;242:1276-1278.</p>
<p>3. Prystowsky SD, Allen AM, Smith RW, Nonomura JH, Odom RB, Akers WA. Allergic contact <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to nickel, neomycin, ethylenediamine, and benzocaine: relationships between age, sex, history of exposure, and reactivity to standard patch and use tests in a general population. <span class="Italics">Arch Dermatol</span>. 1979;115:959-962.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p>Dist. by:</p>
<p><span class="Bold">FALCON Pharmaceuticals, Ltd.</span></p>
<p>Fort Worth, Texas 76134 USA</p>
<p>Mfd. by:</p>
<p><span class="Bold">ALCON LABORATORIES, INC.</span></p>
<p>Fort Worth, Texas 76134 USA</p>
<p>Revised: June 2007</p>
<p>9002571-0607 </p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Neomycin and Polymyxin B Sulfates and Hydrocortisone </p>
<p><br></p>
<p>GENERIC: neomycin sulfate, polymyxin b sulfate and hydrocortisone</p>
<p><br></p>
<p>DOSAGE: SUSPENSION</p>
<p><br></p>
<p>ADMINSTRATION: AURICULAR (OTIC)</p>
<p><br></p>
<p>NDC: 52125-271-01</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul>
<li>HYDROCORTISONE 10mg in 1mL</li>
<li>NEOMYCIN SULFATE 3.5mg in 1mL</li>
<li>POLYMYXIN B SULFATE 10000[USP'U] in 1mL</li>
</ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>ACETIC ACID</li>
<li>POLYSORBATE 80</li>
<li>PROPYLENE GLYCOL</li>
<li>CETYL ALCOHOL</li>
<li>THIMEROSAL</li>
<li>WATER</li>
</ul>
<p><br></p>
<p>PACKAGING: 10 mL in 1 BOTTLE, PLASTIC</p>
<p><br></p>
<p><br></p>
<p><img alt="MM5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c03c099d-dd34-4731-8f50-ec5c7126f7de&amp;name=MM5.jpg"></p>
<p><img alt="MM6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c03c099d-dd34-4731-8f50-ec5c7126f7de&amp;name=MM6.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE 		
					</strong><br><span class="contentTableReg">neomycin sulfate, polymyxin b sulfate and hydrocortisone suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-271(NDC:61314-645)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">AURICULAR (OTIC)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCORTISONE</strong> (HYDROCORTISONE) </td>
<td class="formItem">HYDROCORTISONE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>NEOMYCIN SULFATE</strong> (NEOMYCIN) </td>
<td class="formItem">NEOMYCIN</td>
<td class="formItem">3.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POLYMYXIN B SULFATE</strong> (POLYMYXIN B) </td>
<td class="formItem">POLYMYXIN B</td>
<td class="formItem">10000 [USP'U]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CETYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>THIMEROSAL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-271-01</td>
<td class="formItem">10 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062488</td>
<td class="formItem">06/13/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>613cf670-9c9e-468f-b1dc-a16dbcacf8e9</div>
<div>Set id: c03c099d-dd34-4731-8f50-ec5c7126f7de</div>
<div>Version: 1</div>
<div>Effective Time: 20130613</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
